256,950 Shares in Inhibrx Biosciences, Inc. $INBX Acquired by Parkman Healthcare Partners LLC

Posted by Francis Steltz on Aug 25th, 2026

Parkman Healthcare Partners LLC acquired a new stake in shares of Inhibrx Biosciences, Inc. (NASDAQ:INBX – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 256,950 shares of the company’s stock, valued at approximately $24,346,000. Inhibrx Biosciences accounts for approximately 2.5% of Parkman Healthcare Partners LLC’s investment portfolio, making the stock its 10th biggest position.

Other large investors have also recently bought and sold shares of the company. Legal & General Group Plc acquired a new stake in Inhibrx Biosciences in the second quarter worth $487,000. The Manufacturers Life Insurance Company acquired a new position in shares of Inhibrx Biosciences in the 2nd quarter valued at $399,000. Quantbot Technologies LP bought a new stake in shares of Inhibrx Biosciences in the 2nd quarter valued at $68,000. Western Standard LLC bought a new stake in shares of Inhibrx Biosciences in the 2nd quarter valued at $4,453,000. Finally, NewEdge Wealth LLC acquired a new stake in Inhibrx Biosciences during the 2nd quarter worth $332,000. Institutional investors own 82.46% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on INBX. HC Wainwright began coverage on Inhibrx Biosciences in a report on Monday. They set a “buy” rating and a $245.00 target price on the stock. Wall Street Zen downgraded Inhibrx Biosciences from a “hold” rating to a “strong sell” rating in a report on Monday, August 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inhibrx Biosciences in a research report on Tuesday, June 16th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $197.50.

Get Our Latest Report on INBX

Inhibrx Biosciences Stock Up 1.3%

Inhibrx Biosciences stock opened at $104.94 on Tuesday. The stock has a market capitalization of $1.54 billion, a PE ratio of -11.82 and a beta of 3.51. Inhibrx Biosciences, Inc. has a twelve month low of $24.27 and a twelve month high of $155.29. The company has a quick ratio of 5.07, a current ratio of 5.07 and a debt-to-equity ratio of 12.58. The company has a 50 day moving average of $91.85 and a 200-day moving average of $89.52.

Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($2.34) EPS for the quarter, missing analysts’ consensus estimates of ($2.28) by ($0.06). On average, equities research analysts anticipate that Inhibrx Biosciences, Inc. will post -10.88 EPS for the current fiscal year.

Inhibrx Biosciences Company Profile

(Free Report)

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.